About us

Our Philosophy and Investment Strategy …

should convince you of the uniqueness of the Boehringer Ingelheim Venture Fund (BIVF) as a visionary, trustful and value-adding partner.

Strategic: Create options for the corporation to expand into new therapeutic approaches and businesses
Add value: Help innovators develop their concept from idea to Proof of Concept
Secure financial return to support continuity → Evergreen Fund Model

Boehringer Ingelheim has built a strong pipeline based on in-house R&D
Our Investment Professionals have a hands-on-mentality and strong background in pharma industry
Upon request, we can provide scientific, managerial and commercial support
Since we have no fund-life-time, we can support our portfolio companies from company creation up to an exit - which is our preferred model

Immunomodulation, esp. Immuno-Oncology
Tissue Regeneration, e.g. stem cells, NCEs, biologics
New Therapeutic Modalities, e.g. genetherapy, cell-based therapeutics
Microbiome, esp. approaches based on NCEs and biologics
Antiinfectives with new mechanism of action
Patients Care Management, e.g. diagnosis and monitoring of disease, prevention of onset and progression of disease (incl. digital biomarkers), population management
Medication adherence
Digital companion therapy
Digital therapy as stand alone

Total fund volume: €300 million (€250 million for Therapeutics and €50 million for Digital Health)
Initial investment at an early stage of company's life
Follow-on investments in pace with the company's progress
Staged investments of up to €15 million over company's lifetime (up to €7.5 million for Digital Health companies)

Strategic orientation: Long-term view
Family owned: Continuity, Cultural Identity
No option required, no strings attached: Openness to syndicate with corporate VCs and institutional VCs
Successful track record in R&D: Able and willing to provide scientific, managerial and commercial support
Help positioning portfolio companies for an exit